Neogenix to commence its phase 1 NPC-IC trial

Recommend to others!

Neogenix’s ground breaking phase 1 therapeutic antibody, NPC-1C trial for pancreatic or colorectal cancer received a green signal from the researches at Duke University Medical Center.

NPC-1C is Neogenix’z innovative monoclonal antibody developed with a view to treating advanced pancreatic and colorectal cancer. This is first of its kind trial in company’s pipeline aiming to target specific cancers. Even in pre-clinical studies showed that NPC-1C has certain properly to target pancreatic and colorectal cancer.

Expressing happiness to be in partnership with the investigators at Duke University Medical Center, Neogenix Chief Executive Officer, Philip M. Arlen said that his company is happy with Duke’s joining Johns Hopkins on this study and he feels optimistic to establish the relationship with both of these celebrated medical institutions for future Neogenix therapeutic development. The most fatal cancers like pancreatic ones call for serious medical need for developing new therapies which have few treatments options. With the advancement in treatment particularly aiming to target cancer and spare healthy organs would mean path-breaking advancements to the treatment of the disease.

Michael A. Morse, M.D,., associate professor of medicine at Duke University Medical Center, Principal Investigator on the study said that he feels pleased that he had participated in the clinical valuation aiming to stiudy population with targeted treatment options.



Speak Your Mind


Current day month ye@r *